Multiple Myeloma

Cellular medicine could represent the next frontier in the treatment of patients with cancer and many other diseases with a high unmet need.

Omar Nadeem, MD, discusses the uptake of novel therapies in heavily pretreated multiple myeloma.

Shaji K. Kumar, MD, discusses the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.

Despite the failure of several strategies to improve the outcomes of patients with newly diagnosed diffuse large B-cell lymphoma, there appears to be substantial and growing progress in the treatment of relapsed disease.

Experts in multiple myeloma comment on standard induction therapy for patients with newly diagnosed symptomatic myeloma and consider recommended triplet regimens.

The BNT162b2 mRNA COVID-19 vaccine may demonstrate decreased efficacy in patients with certain types of hematologic cancers, such as chronic lymphocytic leukemia and multiple myeloma.

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss the diagnostic work-up for a patient with newly diagnosed multiple myeloma and the impact of age and frailty scores on transplant eligibility.

The FDA has approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro) plus pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy, including lenalidomide and a proteasome inhibitor

Although the armamentarium of multiple myeloma is rich with available treatment options, novel triplet regimens, maintenance therapies, and targets beyond BCMA are further expanding the paradigm across the newly diagnosed, early-relapse, and late-relapse disease states.

The combination of INN melphalan flufenamide and dexamethasone was found to induce a superior progression-free survival benefit over pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma who had previously received 2 to 4 lines of therapy, meeting the primary end point of the phase 3 OCEAN trial.

Adam Sperling, MD, PhD, discusses future research directions with idecabtagene vicleucel for the treatment of patients with multiple myeloma.

Faith Davies, MD, discusses the approval of isatuximab-irfc-based combinations for patients with relapsed/refractory multiple myeloma.

Faith E. Davies, MD, discusses the next steps for CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

Omar Nadeem, MD, discusses the integration of isatuximab-irfc in relapsed/refractory multiple myeloma.

Thomas G. Martin, MD, speaks to the FDA approval of isatuximab, carfilzomib, and dexamethasone, and potential future directors for isatuximab.

Key opinion leaders remark about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.

Factors to consider when choosing the optimal treatment approach after the first relapse of multiple myeloma.

The European Commission has granted marketing authorization for the expanded use of subcutaneous daratumumab for use in 2 new indications.

Giada Bianchi, MD, discusses diagnostic factors for light chain amyloidosis.

Omar Nadeem, MD, discusses the emergence of quadruplet regimens in multiple myeloma.

The expanding therapeutic landscape in multiple myeloma is poised to integrate daratumumab-based quadruplet therapies and novel cellular therapies as standard options for patients with newly diagnosed and relapsed/refractory disease.

C. Ola Landgren, MD, PhD, focuses on the cellular- and immunotherapy-based elements from the event and where these modern therapies optimally fit in multiple myeloma.

James Hoffman, MD, and Joshua Richter, MD, discuss the IKEMA study, the appropriate selection of therapy, and the differences between various options.

Experts in the field of multiple myeloma discuss the BOSTON trial, the study design, and the benefits of using selinexor in a patient after CAR T-cell therapy.

Daratumumab-based quadruplet regimens and cutting-edge immune-based therapies are positioned to become potential standard options in frontline multiple myeloma treatment.